Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.

This study is a single-center, open-label Phase II clinical trial, aiming to enroll approximately 30 unresectable BCLC stage B or C hepatocellular carcinoma (HCC) patients from China. The primary objective is to evaluate the safety and efficacy of AK112 (a dual-specific antibody against PD-1/VEGF) in combination with hepatic arterial infusion chemotherapy (HAIC) for the treatment of unresectable hepatocellular carcinoma. All enrolled subjects will receive AK112 (20mg/kg Q3W) combined with HAIC (utilizing the FOLFOX chemotherapy regimen) until the investigator determines no further clinical be

Trial Details

NCT ID
NCT06375486
Phase
PHASE2
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
RECRUITING
Cancer Type
Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions
  • Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）
Locations (sample)
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

  • Voluntarily sign a written informed consent form.
  • Age at enrollment is ≥ 18 years and ≤ 75 years, both males and females are eligible.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
  • Expected survival ≥ 3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →